39 related articles for article (PubMed ID: 18469157)
1. [Ⅱ. Timing of HER2 Testing and Medical Treatment for Early Breast Cancer].
Kawabata H
Gan To Kagaku Ryoho; 2023 Dec; 50(12):1274-1277. PubMed ID: 38247064
[No Abstract] [Full Text] [Related]
2. Hydroethanolic Extract of Defatted
Ore A; Adeogun AI; Akinloye OA
Medicines (Basel); 2021 Dec; 9(1):. PubMed ID: 35049934
[No Abstract] [Full Text] [Related]
3. Analysis of HER2 genomic binding in breast cancer cells identifies a global role in direct gene regulation.
Redmond AM; Omarjee S; Chernukhin I; Le Romancer M; Carroll JS
PLoS One; 2019; 14(11):e0225180. PubMed ID: 31747426
[TBL] [Abstract][Full Text] [Related]
4. Potential role of estradiol in ovariectomy-induced derangement of renal endocrine functions.
El-Gendy AA; Elsaed WM; Abdallah HI
Ren Fail; 2019 Nov; 41(1):507-520. PubMed ID: 31216906
[TBL] [Abstract][Full Text] [Related]
5. S100β as a serum marker in endocrine resistant breast cancer.
Charmsaz S; Hughes É; Bane FT; Tibbitts P; McIlroy M; Byrne C; Cocchiglia S; McBryan J; Hennessy BT; Dwyer RM; Kerin MJ; Hill AD; Young LS
BMC Med; 2017 Apr; 15(1):79. PubMed ID: 28399921
[TBL] [Abstract][Full Text] [Related]
6. FKBPL: a marker of good prognosis in breast cancer.
Nelson L; McKeen HD; Marshall A; Mulrane L; Starczynski J; Storr SJ; Lanigan F; Byrne C; Arthur K; Hegarty S; Ali AA; Furlong F; McCarthy HO; Ellis IO; Green AR; Rakha E; Young L; Kunkler I; Thomas J; Jack W; Cameron D; Jirström K; Yakkundi A; McClements L; Martin SG; Gallagher WM; Dunn J; Bartlett J; O'Connor D; Robson T
Oncotarget; 2015 May; 6(14):12209-23. PubMed ID: 25906750
[TBL] [Abstract][Full Text] [Related]
7. The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.
Dittrich A; Gautrey H; Browell D; Tyson-Capper A
J Mammary Gland Biol Neoplasia; 2014 Dec; 19(3-4):253-70. PubMed ID: 25544707
[TBL] [Abstract][Full Text] [Related]
8. Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells.
Redmond AM; Byrne C; Bane FT; Brown GD; Tibbitts P; O'Brien K; Hill AD; Carroll JS; Young LS
Oncogene; 2015 Jul; 34(29):3871-80. PubMed ID: 25284587
[TBL] [Abstract][Full Text] [Related]
9. COX2 expression in high-grade breast cancer: evidence for prognostic significance in the subset of triple-negative breast cancer patients.
Chikman B; Vasyanovich S; Lavy R; Habler L; Tolstov G; Kapiev A; Halevy A; Sandbank J
Med Oncol; 2014 Jun; 31(6):989. PubMed ID: 24816739
[TBL] [Abstract][Full Text] [Related]
10. Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5.
Ward TM; Iorns E; Liu X; Hoe N; Kim P; Singh S; Dean S; Jegg AM; Gallas M; Rodriguez C; Lippman M; Landgraf R; Pegram MD
Oncogene; 2013 May; 32(19):2463-74. PubMed ID: 22751112
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer.
Schillaci R; Guzmán P; Cayrol F; Beguelin W; Díaz Flaqué MC; Proietti CJ; Pineda V; Palazzi J; Frahm I; Charreau EH; Maronna E; Roa JC; Elizalde PV
BMC Cancer; 2012 Feb; 12():74. PubMed ID: 22356700
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 and human epidermal growth factor receptor type 2 (HER-2) expression simultaneously in invasive and in situ breast ductal carcinoma.
Lucarelli AP; Martins MM; Montor W; Oliveira V; Galvão MA; Piato S
Sao Paulo Med J; 2011 Dec; 129(6):371-9. PubMed ID: 22249792
[TBL] [Abstract][Full Text] [Related]
13. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer.
McCartan D; Bolger JC; Fagan A; Byrne C; Hao Y; Qin L; McIlroy M; Xu J; Hill AD; Gaora PÓ; Young LS
Cancer Res; 2012 Jan; 72(1):220-9. PubMed ID: 22072566
[TBL] [Abstract][Full Text] [Related]
14. Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours.
Caiazza F; McCarthy NS; Young L; Hill AD; Harvey BJ; Thomas W
Br J Cancer; 2011 Jan; 104(2):338-44. PubMed ID: 21119660
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients.
Dillon MF; Stafford AT; Kelly G; Redmond AM; McIlroy M; Crotty TB; McDermott E; Hill AD; Young LS
Endocr Relat Cancer; 2008 Sep; 15(3):745-53. PubMed ID: 18469157
[TBL] [Abstract][Full Text] [Related]
16. Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen.
Bergqvist J; Elmberger G; Ohd J; Linderholm B; Bjohle J; Hellborg H; Nordgren H; Borg AL; Skoog L; Bergh J
Eur J Cancer; 2006 May; 42(8):1104-12. PubMed ID: 16603346
[TBL] [Abstract][Full Text] [Related]
17. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
18. Expression of HER2 and its association with AP-2 in breast cancer.
Pellikainen J; Naukkarinen A; Ropponen K; Rummukainen J; Kataja V; Kellokoski J; Eskelinen M; Kosma VM
Eur J Cancer; 2004 Jul; 40(10):1485-95. PubMed ID: 15196531
[TBL] [Abstract][Full Text] [Related]
19. The cerebrovascular risks associated with tamoxifen use.
Bushnell C
Expert Opin Drug Saf; 2005 May; 4(3):501-7. PubMed ID: 15934856
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
